On July 13, 2026, the Department of Justice and the Federal Trade Commission (FTC) (together, the “Agencies”) resolved allegations that Edwards Lifesciences Corp. (“Edwards”) intentionally structured its acquisition of JC Medical Inc. (“JC Medical”) from Genesis MedTech Group Limited (“Genesis”) to evade the notification and waiting-period requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”).1 The settlement imposes a combined USD12m penalty on the parties and is the largest fine ever imposed for failing to make an HSR filing.
Edwards’ acquisition of JC Medical was structured with two components. On July 22, 2024, Edwards acquired JC Medical from Genesis for USD115m, then subsequently acquired USD25m of non-voting shares in Genesis on August 9, 2024.